Peptides marketed for weight loss AOD 9604, BPC-157, tesofensine analogs, and similar compounds are discussed in the context of the evidence (or lack of evidence) supporting their use for weight management
At present, several oral antidiabetic medications are used for the treatment of T2DM including, -glucosidases inhibitors, biguanides, sulfonylureas, meglitinides, GLP-1 receptor agonists (GLP-1RAs), peroxisome proliferator-activated receptor (PPAR-) agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, and sodiumglucose transporter 2 (SGLT2) inhibitors
This is the stuff that matters
Some clients describe temporary sensations such as warmth, pressure or mild discomfort at the injection site
Add a GLP-1 agonist if further glycaemic or weight reduction is needed
The difference rarely comes down to the peptide itself